Skip to main content
Keyword
Specialties
Allergy & Immunology
Autoimmune
CardioVascular
Clinical Pathways
Dentistry
Dermatology
Emergency & Mobile Medicine
Endocrinology & Diabetes
Gastroenterology
Infectious Diseases
Neurology
Obstetrics & Gynecology
Oncology
Ophthalmology
Pediatrics
Podiatry
Population Health
Psychiatry & Behavioral Health
Pulmonology
Rheumatology & Arthritis
Surgery
Urology
Wound Care
Events
Education
About
Sign In
Search
Keyword
Specialties
Allergy & Immunology
Autoimmune
CardioVascular
Clinical Pathways
Dentistry
Dermatology
Emergency & Mobile Medicine
Endocrinology & Diabetes
Gastroenterology
Infectious Diseases
Neurology
Obstetrics & Gynecology
Oncology
Ophthalmology
Pediatrics
Podiatry
Population Health
Psychiatry & Behavioral Health
Pulmonology
Rheumatology & Arthritis
Surgery
Urology
Wound Care
Events
Education
About
Sign In
Search
Michal Weingart, PhD
Lumateperone (ITI-007) for the Treatment of Schizophrenia: Overview of Placebo-Controlled Clinical Trials and an Open-label Safety Switching Study
Background: Lumateperone is a first-in-class agent in development for schizophrenia that acts synergistically through serotonergic, dopaminergic and glutamatergic systems.
Kimberly Vanover , PhD;
Jelena Saillard , MS, MBA;
Steven Glass , MD;
Susan Kazaouer , MD;
Michal Weingart , PhD;
Robert Davis , PhD;
Andrew Satlin , MD;
Sharon Mates , PhD;
03/01/2019
Featured Webinar
Implementing ERAS Protocols Throughout Patient Peri-Op Journey: Reductions in Complications
Upcoming Events
February 2 – February 5
February 27 – March 1
March 17 – March 19
March 27 – March 30
March 31 – April 2
April 21 – April 24
April 30 – May 4
April 30 – May 5
May 1 – May 3
May 19 – May 21
See Full Calendar